Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Jefferies cuts BioPharma Credit to hold on cash drag risk

Published 07/02/2024, 14:18
© Reuters.

On Wednesday, investment firm Jefferies downgraded BioPharma Credit PLC (BPCR:LN), shifting its stance from Buy to Hold. The adjustment follows observations of significant loan repayment and prepayment actions within the first half of the year, potentially resulting in a substantial cash balance for the company.

The firm's analyst noted that should BioPharma Credit not secure new investment opportunities, the company could end up with a cash balance that approximates 50% of its net asset value (NAV). This scenario is anticipated due to the high level of loan repayment and prepayment activity noted over the period.

Moreover, with several loans approaching the end of their make-whole periods, there is an increased possibility of additional cash drag. This situation is a key factor influencing the decision to downgrade the stock. The make-whole period is a timeframe during which a borrower must pay a penalty if they repay a loan before its set maturity date.

The potential for a larger cash balance and the risk of further cash drag due to the expiry of make-whole periods have prompted Jefferies to take a more cautious view of BioPharma Credit's stock. The firm's new rating reflects concerns over the impact of these factors on the company's financial performance.

Investors are now watching to see how BioPharma Credit will manage its cash position and whether the company will be able to mitigate the risks associated with the impending expiry of make-whole periods. The outcome of these developments will likely influence the future performance of the company's stock.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.